Advertisement

U.S. Markets open in 2 hrs 44 mins

S&P Futures
4,566.00
-9.75(-0.21%)
Dow Futures
34,560.00
-62.00(-0.18%)
Nasdaq Futures
15,956.25
-32.25(-0.20%)
Russell 2000 Futures
2,199.00
-6.20(-0.28%)
Crude Oil
67.99
+1.49(+2.24%)
Gold
1,772.30
+9.60(+0.54%)

Advertisement

November jobs report: Payrolls likely grew by 550,000 and unemployment rate fell to 4.5%

Check back for results at 8:30 a.m. ET

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

66.63

+1.67

(+2.57%)

At close: 04:00PM EST

68.15

+1.52

(+2.28%)

Pre-Market:

05:51AM EST

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

Zacks
Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR Newswire
OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis
OLUMIANT® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeti
Business Wire
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del., November 09, 2021--Incyte to Present at Upcoming Investor Conference